Search Videos and More
News
Dana-Farber Research Publication 07.15.2024
This twice-monthly newsletter highlights the research endeavors at Dana-Farber Cancer Institute, noting recently published papers available from PubMed where Dana-Farber faculty are listed as first or senior authors.
News
Specially Equipped Natural Killer Cells Show Effectiveness Against the Most Common Form of Ovarian Cancer
CAR memory-like NK cells targeting the membrane proximal domain of mesothelin demonstrate promising activity in ovarian cancer
News
Jose Cancelas Named Director of the Connell and O'Reilly Families Cell Manipulation Core Facility at Dana-Farber Cancer Institute
Jose Cancelas, MD, PhD, recently joined Dana-Farber Cancer Institute as the director of the Connell and O'Reilly Families Cell Manipulation Core Facility (CMCF).
News
Researchers Customize AI Tools for Digital Pathology
Scientists from Dana-Farber Cancer Institute and Weill Cornell Medicine have developed and tested new artificial intelligence (AI) tools tailored to digital pathology—a relatively new field that uses high-resolution digital images that are created from tissue samples to diagnose diseases and inform treatment decisions.
Video
Bladder Cancer Highlights presented by Michael Serzan, MD
The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the bladder cancer clinical updates you need to know from ASCO 2024.
Video
Kidney Cancer Highlights presented by Michael Serzan, MD
The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the kidney cancer clinical updates you need to know from ASCO 2024.
Video
Prostate Cancer Highlights presented by Michael Serzan, MD
The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the prostate cancer clinical updates you need to know from ASCO 2024.
News
Study Highlights the Importance of Infection Prevention After CAR T-Cell Therapy
A systematic review and meta-analysis of non-relapse mortality after CAR T-cell therapy.
News
Finding New Vulnerabilities in Uterine and Ovarian Cancers
Just like humans, cells get stressed, too — especially cancer cells. For decades, Dana-Farber researchers have been characterizing a complex molecular condition in cancer cells known as DNA replication stress.
News
Antibody-Drug Conjugate Highly Effective in Preventing Recurrence in Patients with Early Stage HER2+ Breast Cancer, Trial Finds
A year of treatment with a medicine made of an antibody and chemotherapy drug has proven highly effective in preventing stage 1 HER2-positive breast cancer from recurring in patients, a team led by Dana-Farber Cancer Institute researchers has found.
Symposium
2025 American Society of Clinical Oncology (ASCO)
Review video summaries and oral abstracts from Dana-Farber physician-scientists at the ASCO 2025 Annual Meeting.
Symposium
ASCO 2025: GU Highlights
In the following videos, Faculty from Dana-Farber Cancer Institute review GU Oncology highlights from the 2025 ASCO Annual Meeting, held in Chicago, May 30 - June 3, 2025.